WO2021164789A1 - 一种吡唑并嘧啶类化合物的晶型及其应用 - Google Patents
一种吡唑并嘧啶类化合物的晶型及其应用 Download PDFInfo
- Publication number
- WO2021164789A1 WO2021164789A1 PCT/CN2021/077255 CN2021077255W WO2021164789A1 WO 2021164789 A1 WO2021164789 A1 WO 2021164789A1 CN 2021077255 W CN2021077255 W CN 2021077255W WO 2021164789 A1 WO2021164789 A1 WO 2021164789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- compound
- formula
- angles
- ray powder
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 182
- -1 pyrazolopyrimidine compound Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 154
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract description 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims abstract description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims abstract description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims abstract description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims abstract description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims abstract description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 91
- 238000001228 spectrum Methods 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000012065 filter cake Substances 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 230000004580 weight loss Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 229940126062 Compound A Drugs 0.000 claims description 13
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 13
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 238000001757 thermogravimetry curve Methods 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 54
- 239000000243 solution Substances 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 238000003756 stirring Methods 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000011521 glass Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000001291 vacuum drying Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 102000038030 PI3Ks Human genes 0.000 description 12
- 108091007960 PI3Ks Proteins 0.000 description 12
- 230000005855 radiation Effects 0.000 description 12
- 101150037263 PIP2 gene Proteins 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000012054 celltiter-glo Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229940124291 BTK inhibitor Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000013043 cell viability test Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 2
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000004455 differential thermal analysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 101150073900 PTEN gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention relates to a crystal form of a pyrazolo pyrimidine compound and a preparation method thereof, and relates to the preparation and treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, follicular lymphoma, and mantle cell lymphoma. Tumors and diffuse large B-cell lymphoma related diseases.
- Phosphatidylinositol 3-kinase (phosphatidylinositol-3-kinase, PI3K) is composed of regulatory subunit p85 or p101, and catalytic subunit p110 (subdivided into four subtypes: p110a, p110b, p110g, and p110d)
- Lipid kinase catalyzes the phosphorylation of the inositol ring 3'-OH of phosphatidylinositol 4,5-bisphosphate (phosphatidylinositol 4,5-bisphosphate, PIP2) to phosphatidylinositol 3,4,5-triphosphate (phosphatidylinositol 4,5-bisphosphate, PIP2). 3,4,5-trisphosphate, PIP3) and activate downstream Akt, which plays a key role in cell proliferation, survival and metabolism. In tumor cells, PI3K is overexpressed, which leads to
- the tumor suppressor gene PTEN (phosphatase, tension homolog deleted on chromosome ten) dephosphorylates PIP3 to generate PIP2, which leads to negative feedback regulation of the PI3K signaling pathway, inhibits cell proliferation and promotes cell apoptosis.
- PTEN phosphatase, tension homolog deleted on chromosome ten
- TGR-1202 is a second-generation PI3K ⁇ inhibitor developed by TG Therapeutic. Compared with the first-generation PI3K ⁇ inhibitor, it can significantly reduce the toxicity of liver and gastrointestinal tract in clinical trials, and patients with large B-cell lymphoma are also exposed to TGR. -1202 There is a partial response.
- Patent WO2014006572 discloses the structure of TGR-1202.
- ACP-196 is a second-generation BTK inhibitor that has been approved for marketing by the FDA. It has been reported in the literature (PLoS ONE 12(2):e0171221.). The combination of PI3K ⁇ inhibitors and BTK inhibitors can jointly inhibit BCR signaling from two aspects. Access, thereby playing a synergistic effect.
- the present invention provides crystal form A of the compound of formula (I), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 7.92 ⁇ 0.20°, 8.82 ⁇ 0.20°, 17.24 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.92 ⁇ 0.20°, 8.82 ⁇ 0.20°, 16.22 ⁇ 0.20°, 17.24 ⁇ 0.20°, 19.78 ⁇ 0.20°, 23.30 ⁇ 0.20°, 24.96 ⁇ 0.20°, 26.00 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.92 ⁇ 0.20°, 8.82 ⁇ 0.20°, 14.78 ⁇ 0.20°, 16.22 ⁇ 0.20°, 17.24 ⁇ 0.20°, 19.78 ⁇ 0.20°, 21.84 ⁇ 0.20°, 23.30 ⁇ 0.20°, 24.96 ⁇ 0.20°, 26.00 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction at the following 2 ⁇ angles: 4.80°, 7.92°, 8.82°, 10.26°, 11.94°, 13.82°, 14.78°, 15.46° , 16.22°, 17.24°, 18.26°, 19.78°, 21.12°, 21.84°, 22.70°, 23.30°, 24.20°, 24.96°, 26.00°, 26.58°, 27.74°, 28.56°, 29.40°, 30.76°, 32.24 °, 37.18°.
- the XRPD pattern of the above-mentioned crystal form A is shown in FIG. 1.
- the XRPD pattern analysis data of the above-mentioned crystal form A is shown in Table 1:
- the differential scanning calorimetry curve of the above crystal form A has an endothermic peak at 188.9 ⁇ 3.0°C and an exothermic peak at 414.7 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form A is shown in FIG. 2.
- thermogravimetric analysis curve of the above-mentioned crystal form A has a weight loss of 0.21% at 200.0°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form A is shown in FIG. 3.
- the present invention also provides the B crystal form of the compound of formula (I), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 10.30 ⁇ 0.20°, 11.96 ⁇ 0.20°, 19.94 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 10.30 ⁇ 0.20°, 11.96 ⁇ 0.20°, 18.04 ⁇ 0.20°, 19.94 ⁇ 0.20°, 21.54 ⁇ 0.20°, 22.72 ⁇ 0.20°, 23.58 ⁇ 0.20°, 26.18 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 10.30 ⁇ 0.20°, 11.96 ⁇ 0.20°, 13.06 ⁇ 0.20°, 18.04 ⁇ 0.20°, 19.94 ⁇ 0.20°, 21.54 ⁇ 0.20°, 22.72 ⁇ 0.20°, 23.58 ⁇ 0.20°, 26.18 ⁇ 0.20°, 26.98 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction at the following 2 ⁇ angles: 9.10°, 10.30°, 11.96°, 13.06°, 14.36°, 14.96°, 16.98°, 18.04° , 19.94°, 21.54°, 22.72°, 23.58°, 26.18°, 26.98°, 28.40°, 29.74°, 36.66°.
- the XRPD pattern of the above-mentioned crystal form B is shown in FIG. 4.
- the XRPD pattern analysis data of the above-mentioned crystal form B is shown in Table 2:
- the differential scanning calorimetry curve of the above-mentioned crystal form B has an endothermic peak at 126.6 ⁇ 3.0°C and 187.9 ⁇ 3.0°C, and an exothermic peak at 415.7 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form B is shown in FIG. 5.
- thermogravimetric analysis curve of the above-mentioned crystal form B has a weight loss of 0.31% at 200.0°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form B is shown in FIG. 6.
- the present invention also provides crystal form C of the compound of formula (I), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 10.28 ⁇ 0.20°, 11.90 ⁇ 0.20°, 23.30 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form C has characteristic diffraction peaks at the following 2 ⁇ angles: 10.28 ⁇ 0.20°, 10.78 ⁇ 0.20°, 11.90 ⁇ 0.20°, 12.86 ⁇ 0.20°, 17.92 ⁇ 0.20°, 22.88 ⁇ 0.20°, 23.30 ⁇ 0.20°, 26.26 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form C has characteristic diffraction peaks at the following 2 ⁇ angles: 10.28 ⁇ 0.20°, 10.78 ⁇ 0.20°, 11.90 ⁇ 0.20°, 12.86 ⁇ 0.20°, 14.92 ⁇ 0.20°, 17.92 ⁇ 0.20°, 22.88 ⁇ 0.20°, 23.30 ⁇ 0.20°, 25.52 ⁇ 0.20°, 26.26 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form C has characteristic diffraction at the following 2 ⁇ angles: 7.42°, 8.36°, 9.04°, 10.28°, 10.78°, 11.90°, 12.86°, 14.38° , 14.92°, 16.06°, 16.74°, 17.92°, 19.06°, 19.94°, 20.58°, 21.28°, 22.88°, 23.30°, 23.76°, 25.52°, 26.00°, 26.26°, 26.94°, 27.93°, 28.90 °, 29.96°, 30.63°, 31.30°, 32.32°, 33.28°, 33.90°.
- the XRPD pattern of the above-mentioned crystal form C is shown in FIG. 7.
- the XRPD pattern analysis data of the above-mentioned crystal form C is shown in Table 3:
- the differential scanning calorimetry curve of the above crystal form C has an endothermic peak at 122.0 ⁇ 3.0°C and 180.1 ⁇ 3.0°C, respectively.
- the DSC spectrum of the above-mentioned crystal form C is shown in FIG. 8.
- thermogravimetric analysis curve of the above-mentioned crystal form C has a weight loss of 4.31% at 200.0°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form C is shown in FIG. 9.
- the present invention also provides the D crystal form of the compound of formula (I), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 10.10 ⁇ 0.20°, 11.56 ⁇ 0.20°, 22.90 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form D has characteristic diffraction peaks at the following 2 ⁇ angles: 10.10 ⁇ 0.20°, 11.56 ⁇ 0.20°, 17.80 ⁇ 0.20°, 19.98 ⁇ 0.20°, 20.80 ⁇ 0.20°, 22.90 ⁇ 0.20°, 23.68 ⁇ 0.20°, 25.68 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form D has characteristic diffraction peaks at the following 2 ⁇ angles: 10.10 ⁇ 0.20°, 11.56 ⁇ 0.20°, 14.68 ⁇ 0.20°, 17.80 ⁇ 0.20°, 19.98 ⁇ 0.20°, 20.80 ⁇ 0.20°, 22.90 ⁇ 0.20°, 23.68 ⁇ 0.20°, 25.00 ⁇ 0.20°, 25.68 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form D has characteristic diffraction at the following 2 ⁇ angles: 4.48°, 8.26°, 9.00°, 10.10°, 10.56°, 11.56°, 12.40°, 12.72° , 14.26°, 14.68°, 15.90°, 16.56°, 17.80°, 18.76°, 19.58°, 19.98°, 20.26°, 20.80°, 21.28°, 21.72°, 22.90°, 23.68°, 25.00°, 25.68°, 26.20 °, 26.84°, 27.88°, 28.74°, 29.46°, 29.96°, 30.80°, 32.18°, 32.86°, 33.60°, 33.98°, 35.90°, 37.46°, 38.36°.
- the XRPD pattern of the above-mentioned crystal form D is shown in FIG. 10.
- the XRPD pattern analysis data of the above-mentioned crystal form D is shown in Table 4:
- the differential scanning calorimetry curve of the above-mentioned crystal form D has an endothermic peak at 129.2 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form D is shown in FIG. 11.
- thermogravimetric analysis curve of the above-mentioned crystal form D has a weight loss of 9.06% at 200.0°C ⁇ 3.0°C.
- the TGA spectrum of the above-mentioned crystal form D is shown in FIG. 12.
- the present invention provides compounds of formula (II).
- n is selected from 1 to 2, preferably 1 or 1.1 or 2.
- the present invention also provides the E crystal form of the compound of formula (II), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 4.14 ⁇ 0.20°, 7.56 ⁇ 0.20°, 14.61 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form E has characteristic diffraction peaks at the following 2 ⁇ angles: 4.14 ⁇ 0.20°, 7.56 ⁇ 0.20°, 9.46 ⁇ 0.20°, 14.61 ⁇ 0.20°, 15.30 ⁇ 0.20°, 19.39 ⁇ 0.20°, 22.00 ⁇ 0.20°, 25.09 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form E has characteristic diffraction peaks at the following 2 ⁇ angles: 4.14 ⁇ 0.20°, 7.56 ⁇ 0.20°, 9.46 ⁇ 0.20°, 12.40 ⁇ 0.20°, 14.61 ⁇ 0.20°, 15.30 ⁇ 0.20°, 19.39 ⁇ 0.20°, 20.33 ⁇ 0.20°, 22.00 ⁇ 0.20°, 25.09 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form E has characteristic diffraction at the following 2 ⁇ angles: 4.14°, 7.56°, 9.08°, 9.46°, 10.25°, 12.40°, 12.78°, 14.61° , 15.30°, 16.11°, 16.69°, 19.39°, 20.33°, 22.00°, 22.74°, 23.00°, 23.20°, 25.09°, 27.33°.
- the XRPD pattern of the above-mentioned crystal form E is shown in FIG. 13.
- the XRPD pattern analysis data of the above-mentioned crystal form E is shown in Table 5:
- the differential scanning calorimetry curve of the above crystal form E has an endothermic peak at 169.49 ⁇ 3.0°C and 198.33 ⁇ 3.0°C, respectively.
- the DSC spectrum of the above-mentioned crystal form E is shown in FIG. 14.
- thermogravimetric analysis curve of the above crystal form E has a weight loss of 3.453% at 113.05°C ⁇ 3.0°C, and a weight loss of 3.537% at 179.56°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form E is shown in FIG. 15.
- the present invention provides compounds of formula (III).
- m is selected from 0.5 to 2, preferably 0.5 or 1 or 1.1.
- the present invention also provides the F crystal form of the compound of formula (III), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 5.12 ⁇ 0.20°, 6.41 ⁇ 0.20°, 10.38 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form F has characteristic diffraction peaks at the following 2 ⁇ angles: 5.12 ⁇ 0.20°, 6.41 ⁇ 0.20°, 7.54 ⁇ 0.20°, 10.38 ⁇ 0.20°, 12.80 ⁇ 0.20°, 19.98 ⁇ 0.20°, 24.82 ⁇ 0.20°, 25.72 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form F has characteristic diffraction peaks at the following 2 ⁇ angles: 5.12 ⁇ 0.20°, 6.41 ⁇ 0.20°, 7.54 ⁇ 0.20°, 10.38 ⁇ 0.20°, 12.80 ⁇ 0.20°, 13.40 ⁇ 0.20°, 16.24 ⁇ 0.20°, 19.98 ⁇ 0.20°, 24.82 ⁇ 0.20°, 25.72 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form F has characteristic diffraction at the following 2 ⁇ angles: 5.12°, 6.41°, 7.54°, 7.98°, 10.38°, 12.36°, 12.80°, 13.40° , 16.24°, 17.52°, 17.89°, 18.61°, 19.22°, 19.63°, 19.98°, 20.96°, 22.39°, 22.81°, 23.45°, 24.82°, 25.72°, 27.31°, 28.39°, 29.92°, 30.99 °.
- the XRPD pattern of the above-mentioned crystal form F is shown in FIG. 16.
- the XRPD pattern analysis data of the above-mentioned crystal form F is shown in Table 6:
- the differential scanning calorimetry curve of the above crystal form F has an endothermic peak at 126.43 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form F is shown in FIG. 17.
- thermogravimetric analysis curve of the above-mentioned crystal form F has a weight loss of 1.726% at 84.88°C ⁇ 3.0°C, and a weight loss of 6.580% at 185.53°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form F is shown in FIG. 18.
- the present invention provides compounds of formula (IV).
- o is selected from 1.
- the present invention also provides the G crystal form of the compound of formula (IV), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 6.08 ⁇ 0.20°, 8.58 ⁇ 0.20°, 12.21 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form G has characteristic diffraction peaks at the following 2 ⁇ angles: 4.12 ⁇ 0.20°, 5.43 ⁇ 0.20°, 6.08 ⁇ 0.20°, 8.58 ⁇ 0.20°, 12.21 ⁇ 0.20°, 16.83 ⁇ 0.20°, 20.69 ⁇ 0.20°, 21.20 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form G has characteristic diffraction at the following 2 ⁇ angles: 4.12°, 5.43°, 6.08°, 8.58°, 8.80°, 12.21°, 12.40°, 16.63° , 16.83°, 20.69°, 21.20°, 25.02°.
- the XRPD pattern of the above-mentioned crystal form G is shown in FIG. 19.
- the XRPD pattern analysis data of the above-mentioned crystal form G is shown in Table 7:
- the differential scanning calorimetry curve of the above-mentioned crystal form G has an endothermic peak at 149.27 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form G is shown in FIG. 20.
- thermogravimetric analysis curve of the above crystal form G has a weight loss of 0.652% at 99.16°C ⁇ 3.0°C, and a weight loss of 0.888% at 183.57°C ⁇ 3.0°C.
- the TGA spectrum of the above-mentioned crystal form G is shown in FIG. 21.
- the present invention also provides the H crystal form of the compound of formula (IV), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 3.17 ⁇ 0.20°, 6.00 ⁇ 0.20°, 8.50 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form H has characteristic diffraction peaks at the following 2 ⁇ angles: 3.17 ⁇ 0.20°, 6.00 ⁇ 0.20°, 8.50 ⁇ 0.20°, 12.28 ⁇ 0.20°, 15.73 ⁇ 0.20°, 19.87 ⁇ 0.20°, 20.59 ⁇ 0.20°, 21.85 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form H has characteristic diffraction at the following 2 ⁇ angles: 3.17°, 6.00°, 8.50°, 8.76°, 12.28°, 15.73°, 19.87°, 20.59° , 21.85°, 25.96°.
- the XRPD pattern of the above-mentioned crystal form H is shown in FIG. 22.
- the differential scanning calorimetry curve of the above crystal form H has an endothermic peak at 146.13 ⁇ 3.0°C.
- the DSC spectrum of the above-mentioned crystal form H is shown in FIG. 24.
- thermogravimetric analysis curve of the above crystal form H has a weight loss of 4.637% at 167.09°C ⁇ 3.0°C.
- the TGA spectrum of the above-mentioned crystal form H is shown in FIG. 24.
- the present invention provides compounds of formula (V).
- p is selected from 0.5 to 2, preferably 0.5 or 0.67 or 1 or 1.1.
- the present invention also provides the I crystal form of the compound of formula (V), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 5.08 ⁇ 0.20°, 10.23 ⁇ 0.20°, 16.24 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form I has characteristic diffraction peaks at the following 2 ⁇ angles: 5.08 ⁇ 0.20°, 6.30 ⁇ 0.20°, 7.45 ⁇ 0.20°, 10.23 ⁇ 0.20°, 12.60 ⁇ 0.20°, 16.24 ⁇ 0.20°, 19.81 ⁇ 0.20°, 24.56 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form I has characteristic diffraction peaks at the following 2 ⁇ angles: 5.08 ⁇ 0.20°, 6.30 ⁇ 0.20°, 7.45 ⁇ 0.20°, 10.23 ⁇ 0.20°, 12.60 ⁇ 0.20°, 16.24 ⁇ 0.20°, 19.81 ⁇ 0.20°, 20.92 ⁇ 0.20°, 22.19 ⁇ 0.20°, 24.56 ⁇ 0.20°.
- the X-ray powder diffraction pattern of the above crystal form I has characteristic diffraction at the following 2 ⁇ angles: 3.78°, 5.08°, 6.30°, 7.45°, 7.96°, 10.23°, 11.62°, 12.35° , 12.60°, 13.21°, 16.24°, 18.54°, 19.81°, 20.20°, 20.92°, 22.19°, 22.49°, 24.56°, 25.33°, 25.55°, 27.14°, 29.58°.
- the XRPD pattern of the above-mentioned crystal form I is shown in FIG. 25.
- the differential scanning calorimetry curve of the above-mentioned crystal form I has an endothermic peak at 128.77 ⁇ 3.0°C and 162.07 ⁇ 3.0°C, respectively.
- the DSC spectrum of the above-mentioned crystal form I is shown in FIG. 26.
- thermogravimetric analysis curve of the above-mentioned crystal form I has a weight loss of 3.564% at 168.36°C ⁇ 3.0°C.
- the TGA pattern of the above-mentioned crystal form I is shown in FIG. 27.
- the present invention also provides the preparation of the crystal form of compound A of formula (I), including:
- the alcohol solvent is methanol or ethanol
- the present invention also provides that the above-mentioned compound or crystal form A or crystal form B or crystal form C or crystal form D or crystal form E or crystal form F or crystal form G or crystal form H or crystal form I are used in the preparation and treatment of chronic lymphocytic leukemia, Small lymphocytic lymphoma, marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma drugs.
- the crystalline forms of the compound of the present invention are stable, are less affected by light, heat and humidity, and have good drug efficacy for in vivo administration.
- the compound has a broad prospect of preparation; the compound of formula (I) can well inhibit the activity of PI3K kinase, and at the same time has a better effect on PI3K ⁇ / ⁇ / ⁇ .
- High subtype selectivity; the compound of formula (I) has a lower plasma protein binding rate, that is, more free drugs in the body, and exhibits high exposure, low clearance, and good oral biology in mice Availability:
- the combination of the compound of formula (I) and the second-generation BTK inhibitor ACP-196 showed a significant tumor regression effect in the TMD-8 mouse subcutaneous xenograft model.
- the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- the structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the field.
- the single crystal X-ray diffraction method uses the Bruker D8 venture diffractometer to collect the diffraction intensity data of the cultivated single crystal.
- the light source is CuK ⁇ radiation.
- the scanning method ⁇ / ⁇ scanning. After the relevant data is collected, the direct method is further adopted. (Shelxs97) By analyzing the crystal structure, the absolute configuration can be confirmed.
- EtOH stands for ethanol
- MeOH stands for methanol
- TFA trifluoroacetic acid
- TsOH stands for p-toluenesulfonic acid
- mp stands for melting point
- EtSO3H stands for ethanesulfonic acid
- MeSO3H stands for methanesulfonic acid
- THF stands for tetrahydrofuran
- EtOAc stands for ethyl acetate
- NBS stands for N-bromosuccinimide
- Pd(dppf)Cl 2 stands for [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
- Pd( PPh 3 ) 4 represents tetrakis(triphenylphosphine)palladium.
- Test method Approximately 10-20mg sample is used for XRPD detection.
- Light tube voltage 40kV
- light tube current 40mA
- Test method Approximately 10-20mg sample is used for XRPD detection.
- Light tube voltage 40kV
- light tube current 40mA
- Test method Take a sample (4.08mg) and place it in a DSC aluminum pan for testing. Heat the sample from 30°C to 450°C at a temperature increase rate of 10°C/min under a nitrogen condition of 50 mL/min.
- Test method Take a sample (0.5mg ⁇ 1mg) into a DSC aluminum pan for testing, and heat the sample from 30°C to 250°C at a temperature increase rate of 10°C/min under a nitrogen condition of 50mL/min.
- TGA Thermal Gravimetric Analyzer
- Test method Take a sample (5.95 mg) and place it in a TGA alumina crucible for testing. Heat the sample from room temperature to 300°C at a heating rate of 20°C/min under 25mL/min nitrogen conditions.
- TGA Thermal Gravimetric Analyzer
- Test method Take a sample (2 ⁇ 5mg) and place it in a TGA platinum pot for testing. Under 25mL/min nitrogen conditions, at a heating rate of 10°C/min, heat the sample from room temperature to 300°C or a weight loss of 20%.
- Fig. 1 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form of compound A of formula (I).
- Figure 2 is a DSC spectrum of the crystal form of compound A of formula (I).
- Figure 3 is a TGA spectrum of the crystal form of compound A of formula (I).
- Fig. 4 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form of compound B of formula (I).
- Figure 5 is a DSC chart of the crystal form of compound B of formula (I).
- Figure 6 is a TGA spectrum of the crystal form of compound B of formula (I).
- Fig. 7 is an XRPD spectrum of Cu-K ⁇ radiation of the crystalline form C of compound of formula (I).
- Fig. 8 is a DSC chart of the crystal form of compound C of formula (I).
- Figure 9 is a TGA spectrum of the crystal form of compound C of formula (I).
- Fig. 10 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form D of compound of formula (I).
- Figure 11 is a DSC chart of the crystalline form D of compound of formula (I).
- Figure 12 is a TGA spectrum of the crystal form D of compound of formula (I).
- Fig. 13 is an XRPD spectrum of Cu-K ⁇ radiation of the E crystal form of compound of formula (II).
- Fig. 14 is a DSC chart of the crystal form of compound E of formula (II).
- Figure 15 is a TGA spectrum of the crystal form E of compound of formula (II).
- Figure 16 is an XRPD spectrum of Cu-K ⁇ radiation of the F crystal of the compound of formula (III).
- Figure 17 is a DSC chart of the crystal form F of the compound of formula (III).
- Figure 18 is a TGA spectrum of the F crystal form of the compound of formula (III).
- Fig. 19 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form G of compound of formula (IV).
- Fig. 20 is a DSC chart of the crystalline form G of compound of formula (IV).
- Figure 21 is a TGA spectrum of the crystal form G of compound of formula (IV).
- Fig. 22 is an XRPD spectrum of Cu-K ⁇ radiation of the H crystal form of compound of formula (IV).
- Fig. 23 is a DSC chart of the crystal form H of compound of formula (IV).
- Figure 24 is a TGA spectrum of the crystal form H of compound of formula (IV).
- Fig. 25 is an XRPD spectrum of Cu-K ⁇ radiation of the crystalline form of compound I of formula (V).
- Figure 26 is a DSC spectrum of the crystalline form of compound I of formula (V).
- Figure 27 is a TGA spectrum of the crystal form of compound I of formula (V).
- Triethylamine (4.91g, 48.57mmol, 6.76mL, 10eq) was added, and after stirring at -78°C for 1 hour, the reaction solution was raised to 25°C and stirred for 1 hour.
- dichloromethane (20 mL) was added to the reaction solution at 0° C., water (10 mL) was added slowly to quench the reaction, and the reaction was extracted with dichloromethane (30 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the target compound BB-1-8.
- WX001-6 was purified by supercritical fluid chromatography (column: DAICEL CHIRALPAK AD-H (250mm*30mm, 5 ⁇ m); mobile phase: [0.1% ammonia in ethanol]; B%: 22%-22%, 8min) (B It is 0.1% ammonia in ethanol) to obtain the compound of formula (I) (retention time is 2.29 min), and the structure of the compound of formula (I) is confirmed by a single crystal to be correct.
- supercritical fluid chromatography column: DAICEL CHIRALPAK AD-H (250mm*30mm, 5 ⁇ m); mobile phase: [0.1% ammonia in ethanol]; B%: 22%-22%, 8min) (B It is 0.1% ammonia in ethanol) to obtain the compound of formula (I) (retention time is 2.29 min), and the structure of the compound of formula (I) is confirmed by a single crystal to be correct.
- the lipid kinase reaction is carried out under the conditions of a suitable substrate and ATP, followed by two steps to detect the kinase activity with the ADP-Glo TM kit.
- the first step terminate the kinase reaction, in which the residual ATP is completely removed, and only ADP is retained; the second step: add kinase detection reagent to convert ADP into ATP, accompanied by a luciferin/luciferase reaction. Finally, the fluorescence value output is converted into kinase activity.
- the conditions for testing PI3K enzyme activity are shown in Table 13.
- Kit ADP-Glo TM lipid kinase and PIP2:3PS kit (Promega#V1792)
- the kit contains: 1mM PIP2:3PS, 10 ⁇ lipid dilution buffer, 1M magnesium chloride, 10mM ATP, 10mM ADP, ADP-Glo reagent, detection buffer and detection substrate.
- reaction buffer 500mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), pH 7.5, 500mM NaCl, 9mM MgCl 2 ; BSA: 10% stock solution, homemade
- Reaction system 3 ⁇ L enzyme and substrate mixture (1:1) + 2 ⁇ L ATP/MgCl 2 mixture + 5 ⁇ L ADP-Glo reagent + 10 ⁇ L detection reagent.
- the compound was diluted three-fold from the highest concentration of 0.111 mM for a total of 10 concentrations.
- the compound was diluted three-fold from the highest concentration of 1.11 mM for a total of 10 concentrations.
- DMEM medium (Invitrogen, Cat#11965126) to dilute the compound to 10 ⁇ M (1mL medium + 1 ⁇ l 10mM compound stock solution), and dilute in 4 times volume successively, and dilute 8 gradients (40 ⁇ l solution of the previous gradient + 120 ⁇ l dilution gradient The solution).
- the tumor cell lines were cultured in an incubator at 37°C and 5% CO 2 according to the culture conditions shown in Table 2. Passage regularly, and take the cells in the logarithmic growth phase for plating.
- the culture plate is placed at room temperature for 10 minutes to stabilize the luminescence signal.
- the compound of formula (I) can well inhibit the activity of PI3K kinase, and at the same time has a high subtype selectivity for PI3K ⁇ / ⁇ / ⁇ . In addition, it can also well inhibit the phosphorylation level of Akt downstream of PI3K in cells.
- mice Female Balb/c mice as the test animal, after a single administration, the blood concentration of the compound was measured and the pharmacokinetic behavior was evaluated.
- mice 8 healthy adult female Balb/c mice, 4 as the intravenous injection group and 4 as the oral group.
- the compound to be tested is mixed with an appropriate amount of intravenous group solvent (DMSO/PEG200/water (5:45:50v/v/v)), vortexed and sonicated to prepare a clear solution of 1.0 mg/mL, filtered by a microporous membrane for use
- the solvent of the oral group is 0.5% MC/0.2% Tween 80.
- the test compound is mixed with the solvent, vortex and sonicate to prepare a 1.0 mg/mL homogeneous suspension for later use.
- PPB% plasma protein binding rate
- oral administration pharmacokinetic parameters Cmax: the highest concentration of the drug in the body
- F% oral bioavailability
- Oral DNAUC area under the normalized dose curve
- intravenous Pharmacokinetic parameters of administration by injection Vd: apparent volume of distribution
- Cl clearance rate
- T 1/2 half-life
- the compound of formula (I) has a lower plasma protein binding rate, that is, more free drugs in the body, and exhibits high exposure, low clearance rate, and good oral bioavailability in mice.
- Human lymphoma TMD-8 cells (Shanghai Junrui-UFBN1682) were cultured in a monolayer in vitro, and the culture conditions were RPMI 1640 medium with 10% fetal bovine serum, 100U/mL penicillin and 100 ⁇ g/mL streptomycin, 37°C5% CO 2 culture. Use pancreatin-EDTA for routine digestion and passage twice a week. When the cell saturation is 80%-90%, collect the cells, count, and inoculate
- TMD-8 cells (with matrigel, volume ratio 1:1) were subcutaneously inoculated into each mouse when the average volume of the right back tumor reached 99 mm 3 and was administered in groups.
- Vehicle group 0.5% MC/0.2% Tween 80/99.3% water.
- Test compound group Weigh a quantitative test compound in a brown dispensing bottle, add a corresponding volume of solvent and vortex to obtain a uniform suspension or clear solution.
- the experimental index is to investigate whether the tumor growth is inhibited, delayed or cured.
- the tumor diameter was measured with vernier calipers twice a week.
- TGI (%) [1- (Average tumor volume at the end of a certain treatment group-the average tumor volume at the beginning of the treatment group) / (Average tumor volume at the end of the solvent control group- The average tumor volume at the start of treatment in the solvent control group)] ⁇ 100%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
吸湿性特性描述 | 引湿性增重(ΔW%) |
潮解 | 吸收足量水分形成液体 |
极具引湿性 | ΔW%≥15% |
有引湿性 | 15%>ΔW%≥2% |
略有引湿性 | 2%>ΔW%≥0.2% |
无或几乎无吸湿性 | ΔW%<0.2% |
Claims (28)
- 根据权利要求1所述的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.92±0.20°,8.82±0.20°,16.22±0.20°,17.24±0.20°,19.78±0.20°,23.30±0.20°,24.96±0.20°,26.00±0.20°。
- 根据权利要求2所述的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射:7.92±0.20°,8.82±0.20°,14.78±0.20°,16.22±0.20°,17.24±0.20°,19.78±0.20°,21.84±0.20°,23.30±0.20°,24.96±0.20°,26.00±0.20°。
- 根据权利要求3所述的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射:4.80°,7.92°,8.82°,10.26°,11.94°,13.82°,14.78°,15.46°,16.22°,17.24°,18.26°,19.78°,21.12°,21.84°,22.70°,23.30°,24.20°,24.96°,26.00°,26.58°,27.74°,28.56°,29.40°,30.76°,32.24°,37.18°。
- 根据权利要求4所述的A晶型,其XRPD图谱如图1所示。
- 根据权利要求1~5任意一项所述的A晶型,其差示扫描量热曲线在在414.7±3.0℃有一个吸热峰的峰值;在188.9±3.0℃有一个放热峰的峰值。
- 根据权利要求6所述的A晶型,其DSC图谱如图2所示。
- 根据权利要求1~5任意一项所述的A晶型,其热重分析曲线在200.0℃±3.0℃时失重达0.21%。
- 根据权利要求8所述的A晶型,其TGA图谱如图3所示。
- 式(I)化合物的D晶型,其特征在于其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:10.10±0.20°,11.56±0.20°,22.90±0.20°。
- 根据权利要求10所述的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:10.10±0.20°,11.56±0.20°,17.80±0.20°,19.98±0.20°,20.80±0.20°,22.90±0.20°,23.68±0.20°,25.68±0.20°。
- 根据权利要求11所述的D晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射:10.10±0.20°,11.56±0.20°,14.68±0.20°,17.80±0.20°,19.98±0.20°,20.80±0.20°,22.90±0.20°,23.68±0.20°,25.00±0.20°,25.68±0.20°。
- 根据权利要求12所述的D晶型,其XRPD图谱如图10所示。
- 根据权利要求10~13任意一项所述的D晶型,其差示扫描量热曲线在129.2±3.0℃有一个放热峰的峰值。
- 根据权利要求14所述的D晶型,其DSC图谱如图11所示。
- 根据权利要求10~13任意一项所述的D晶型,其热重分析曲线在200.0℃±3.0℃时失重达9.06%。
- 根据权利要求16所述的D晶型,其TGA图谱如图12所示。
- 式(V)化合物的I晶型,其特征在于其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.08±0.20°,10.23±0.20°,16.24±0.20°。
- 根据权利要求19所述的I晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.08±0.20°,6.30±0.20°,7.45±0.20°,10.23±0.20°,12.60±0.20°,16.24±0.20°,19.81±0.20°,24.56±0.20°。
- 根据权利要求20所述的I晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射:5.08±0.20°,6.30±0.20°,7.45±0.20°,10.23±0.20°,12.60±0.20°,16.24±0.20°,19.81±0.20°,20.92±0.20°,22.19±0.20°,24.56±0.20°。
- 根据权利要求21所述的I晶型,其XRPD图谱如图25所示。
- 根据权利要求19~22任意一项所述的I晶型,其差示扫描量热曲线分别在128.77±3.0℃和162.07±3.0℃有一个吸热峰的峰值。
- 根据权利要求23所述的I晶型,其DSC图谱如图26所示。
- 根据权利要求19~22任意一项所述的I晶型,其热重分析曲线在168.36℃±3.0℃时失重达3.564%。
- 根据权利要求25所述的I晶型,其TGA图谱如图27所示。
- 式(I)化合物A晶型的制备,包括:1)将式(I)化合物加入水、醇类或混合溶剂中使其成悬浊液;2)悬浊液在25~40℃下搅拌16~30小时,3)将上述悬浊液过滤,滤饼干燥8~16小时;其中,醇类溶剂为甲醇或乙醇;混合溶剂为乙醇:水(v/v=2:1)、丙酮:水(v/v=2:1)或乙醇:水(v/v=1:3)。
- 根据权利要求1~9任意一项所述A晶型或权利要求10~17任意一项所述D晶型或权利要求18所述的化合物或权利要求19~26任意一项所述I晶型或根据权利要求27所述的方法制备得到的晶型在制备治疗慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、边缘带淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤和弥漫性大B细胞淋巴瘤药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010110671.9 | 2020-02-21 | ||
CN202010110671 | 2020-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021164789A1 true WO2021164789A1 (zh) | 2021-08-26 |
Family
ID=77391877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/077255 WO2021164789A1 (zh) | 2020-02-21 | 2021-02-22 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021164789A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010151735A2 (en) * | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
CN104470923A (zh) * | 2012-07-04 | 2015-03-25 | 理森制药股份公司 | 选择性PI3K δ抑制剂 |
CN104582732A (zh) * | 2012-06-15 | 2015-04-29 | 布里格姆及妇女医院股份有限公司 | 治疗癌症的组合物及其制造方法 |
WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
CN105073197A (zh) * | 2012-11-02 | 2015-11-18 | Tg疗法有限公司 | 抗cd20抗体和pi3激酶选择性抑制剂的组合 |
CN106470996A (zh) * | 2014-07-04 | 2017-03-01 | 鲁平有限公司 | 作为pi3k抑制剂的喹嗪酮衍生物 |
US20170209594A1 (en) * | 2015-06-25 | 2017-07-27 | Immunomedics, Inc. | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors |
CN108310384A (zh) * | 2018-02-05 | 2018-07-24 | 苏州大学 | Pi3k抑制剂在制备治疗血小板数量减少相关疾病药物中的用途 |
WO2020038394A1 (zh) * | 2018-08-21 | 2020-02-27 | 南京明德新药研发有限公司 | 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用 |
-
2021
- 2021-02-22 WO PCT/CN2021/077255 patent/WO2021164789A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010151735A2 (en) * | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
CN104582732A (zh) * | 2012-06-15 | 2015-04-29 | 布里格姆及妇女医院股份有限公司 | 治疗癌症的组合物及其制造方法 |
CN104470923A (zh) * | 2012-07-04 | 2015-03-25 | 理森制药股份公司 | 选择性PI3K δ抑制剂 |
CN105073197A (zh) * | 2012-11-02 | 2015-11-18 | Tg疗法有限公司 | 抗cd20抗体和pi3激酶选择性抑制剂的组合 |
WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
CN106470996A (zh) * | 2014-07-04 | 2017-03-01 | 鲁平有限公司 | 作为pi3k抑制剂的喹嗪酮衍生物 |
US20170209594A1 (en) * | 2015-06-25 | 2017-07-27 | Immunomedics, Inc. | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors |
CN108310384A (zh) * | 2018-02-05 | 2018-07-24 | 苏州大学 | Pi3k抑制剂在制备治疗血小板数量减少相关疾病药物中的用途 |
WO2020038394A1 (zh) * | 2018-08-21 | 2020-02-27 | 南京明德新药研发有限公司 | 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2502941T3 (es) | Método de preparación de compuestos de amida de dihidroindeno, las composiciones farmacéuticas que contienen dichos compuestos y el uso como inhibidor de proteína quinasas | |
Liu et al. | Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1, 2, 4-triazolone moiety as c-Met kinase inhibitors | |
WO2018024208A1 (zh) | Ido1抑制剂及其制备方法和应用 | |
CN109311891A (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
EP3395817A1 (en) | Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor | |
KR20210034058A (ko) | Lsd1억제제의 염 및 이의 결정형 | |
ES2943092T3 (es) | Sal que sirve como inhibidor de Akt y cristal de la misma | |
JP6974618B2 (ja) | Fgfr及びvegfr阻害剤としての化合物の塩形態、結晶形およびその製造方法 | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
WO2021164789A1 (zh) | 一种吡唑并嘧啶类化合物的晶型及其应用 | |
WO2022257965A1 (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
CN106892907B (zh) | 含酰腙结构的喹唑啉类化合物及其应用 | |
CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
CN106866642B (zh) | 含芳基酰腙结构的喹唑啉类化合物及其应用 | |
WO2020228729A1 (zh) | 喹唑啉酮类化合物的晶型及其制备方法 | |
WO2020192637A1 (zh) | 固体形式的brd4抑制剂化合物及其制备方法与应用 | |
CN110167554A (zh) | 一种具有抗癌作用的化合物及其制备方法和应用 | |
WO2020221358A1 (zh) | Wee1抑制剂化合物的晶型及其应用 | |
WO2024027825A1 (zh) | 一种cdk抑制剂及其磷酸盐的多晶型 | |
CN111606891B (zh) | (1,1,1-三氯-2)氨基甲酸酯类衍生物及其制备方法和应用 | |
WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
WO2022016420A1 (zh) | 一种喹唑啉酮类化合物的晶型、其制备方法及应用 | |
WO2023151660A1 (zh) | 一种p2x3受体拮抗剂的结晶形式及其制备方法 | |
WO2023083357A1 (zh) | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21757656 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21757656 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21757656 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/07/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21757656 Country of ref document: EP Kind code of ref document: A1 |